Αποτελέσματα Αναζήτησης
30 Αυγ 2021 · Taken together, the risk of death was significantly higher in older individuals (≥60 years) with anemia compared with younger (<60 years) anemic individuals, whereas the risk of death for thrombocytopenia or neutropenia was comparable in both age groups.
13 Ιαν 2021 · Neutropenia is a serious complication of chemotherapy in patients with solid tumors. The influence of hospital volume on outcomes in patients with neutropenia has been little investigated. We hypothesized that large-volume hospitals would have reduced mortality rates for neutropenic patients compared with small-volume institutions. Methods:
Cancer treatment with myelosuppressive chemotherapy puts patients at risk of developing chemotherapy-induced neutropenia (CIN). Neutropenia predisposes patients to potentially life-threatening complications, including febrile neutropenia (FN), antibiotic use, hospitalization, and increased mortality [1].
29 Νοε 2010 · The average age of included patients was 59.8 years (range, 18-97 years) with 1445 (38.4%) aged 65 and older. Seventy percent (70%) of patients were female with breast cancer representing the most common malignancy (39%) followed by lung cancer (24%), colorectal (14%), lymphoma (15%), and ovary (8%).
16 Απρ 2019 · Neutropenia is associated with an increased risk of mortality and hospitalisation. Strategies, including the prescribing of colony-stimulating growth factors (CSFs), are adopted when a high risk (> 20%) of neutropenic complications are seen in the clinical trial setting.
15 Νοε 2022 · People with CND were more likely to be female (65%), be aged ≥18 years (91%), and have been seen by a hematologist (36%), as compared to other specialties. Among people aged <12 years, a greater proportion was diagnosed with congenital neutropenia (13%-20%) compared with cyclic neutropenia (5%-8%) or CIN (5%-6%) (Table).
23 Απρ 2003 · This review summarizes the clinical consequences of che-motherapy-induced neutropenia (CIN) and describes current efforts to predict which patients are likely to experience neutropenic complications—delays and reductions in chemotherapy doses, FN, bacterial and fungal infections, and septic deaths.
